Navigation Links
OncoGenex to Report Financial Results for Third Quarter 2013 and Address Key Questions from Investors on November 7, 2013
Date:10/30/2013

ormation from the quarterly call by following the new OncoGenex Investor Relations Twitter account at: http://twitter.com/@OncoGenex_IR

ABOUT ONCOGENEX
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at www.OncoGenex.com.

OncoGenex' Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our expected timelines for our SYNERGY and Borealis-1 trials. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
2. OncoGenex Announces Multiple Trials in Progress Presentations at the 2013 ASCO Annual Meeting
3. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
4. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
5. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
6. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
8. Anthera Pharmaceuticals Reports 2013 Third Quarter Financial Results, Clinical and Regulatory Update
9. Hanger Reports Third Quarter 2013 Results
10. Covance Reports Third Quarter Net Revenue Of $607 Million, Pro Forma EPS Of $0.83 And Adjusted Net Orders Of $732 Million
11. Questcor Reports Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014  In recognition of the increased risks ... the flu, pneumonia, shingles and other illnesses, CVS/pharmacy ... September to be Senior Vaccination Month. Because people,s ... important that adults ages 65 years and older ... pharmacists and MinuteClinic nurse practitioners and physician assistants ...
(Date:8/28/2014)... Pa. , Aug. 28, 2014  Robotic ... patients, and media, both for the promise of ... safety. The quick deployment of surgical robots and ... are prompting facilities to evaluate their robotic surgery ... entire surgical team.    ECRI Institute ...
(Date:8/28/2014)... Aug. 28, 2014  A decline in revenues ... are adding pressure to pharmaceutical, biotechnology and medical ... continue to shrink and approval processes and postapproval ... companies to look for additional support and expertise ... keeping approved products on the market.  ...
Breaking Medicine Technology:September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 2September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 3September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 2Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 54 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 24 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 34 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 4
... 2007 /PRNewswire-USNewswire/ -- The,following statement may be attributed ... Medical Research (CAMR): , "In the face of ... the stroke of his veto pen deliberately to ... well as endanger,the future health and well being ...
... - Elixir,Pharmaceuticals, Inc., announced today the publication ... (mitiglinide calcium,hydrate) monotherapy, or combination therapy with ... meals. The data were,published in the Abstract ... Scientific Sessions in Chicago, Illinois.,Glufast is an ...
Cached Medicine Technology:President Bush Ignores America's Plea for Support of Stem Cell,Research 2Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 2Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 3Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 4Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 5
(Date:8/28/2014)... Recently, iFitDress.com, the popular online supplier of wedding dresses ... range of fashionable bridesmaid dresses . Along with that, ... are offered with big discounts, from 15 to 65 percent ... 16. , The company’s experienced workers never compromise on ... all its products are trendy and graceful. , “We are ...
(Date:8/28/2014)... DE (PRWEB) August 28, 2014 Blood's Thicker ... gunplay, sex, money and family ties in the heart of ... no other – a story about how disrespect caused two ... limbs on many streets. , The Yayo Boyz and the ... news reporters speechless and local onlookers in a silent terror. ...
(Date:8/28/2014)... 2014 Millennium Treatment Group is ... This month will be a celebration of the ... services. Along with other treatment facilities and mental ... spread the word about this national observance. , ... work of treatment and recovery professionals, and has ...
(Date:8/28/2014)... 2014 Millennium Treatment Group recently announced a ... large, and Millennium Treatment Group is working to close it, ... need. , According to the National Survey on Drug ... Americans could have benefited from treatment for drug and/or substance ... This means that there is a large treatment gap in ...
(Date:8/28/2014)... Ariz. (PRWEB) August 28, 2014 Arizona ... Force Impact Technologies , has been named one of ... the Year competition. , This is the fourth consecutive ... in the competition. Jared Schoepf, co-founder of SafeSIPP, and ... 2013 and 2012, respectively. In 2011, ASU dominated the ...
Breaking Medicine News(10 mins):Health News:Fashionable Bridesmaid Dresses for Autumn 2014 from iFitDress.com 2Health News:Raymond E. Blake Releases Blood's Thicker Than Water, Based on a True Story 2Health News:Millennium Treatment Group Celebrates National Recovery Month 2Health News:Millennium Treatment Group Works to Close Treatment Gap 2Health News:Arizona State University Grad Student in the Running for College Entrepreneur of the Year 2Health News:Arizona State University Grad Student in the Running for College Entrepreneur of the Year 3
... and CHICAGO, Jan. 14 Aon ... advisor, released today a preliminary forecast of direct ... Ponzi scheme.(Logo: http://www.newscom.com/cgi-bin/prnh/20041215/CGW049LOGO )"While the maximum ... over $6 billion, the range of direct insured ...
... who want a baby, study says, , , WEDNESDAY, Jan. 14 (HealthDay ... vitro fertilization have up to an 86 percent chance of giving ... the odds are less than 50 percent -- in some cases, ... infertility, and it can overcome most causes of infertility for those ...
... Chaka Fattah (D-PA) issues the following statement upon passage by ... by a bipartisan vote of 289 to 139. ... to bring change to Washington by expanding health care for ... today. I have joined with more than two-thirds of my ...
... treatment of liver disease, study says , , WEDNESDAY, Jan. 14 ... not appear to help Hispanic whites with the liver disease ... suggests. , This is second major ethnic group -- the ... the therapy, consisting of pegylated interferon with ribavirin, in recent ...
... is being adopted in the U.S. and around the world, ... simple checklist that ensures everyone in the operating room is ... report. , The need for improving safety in surgery is ... each year, 60 million of them in the United States. ...
... National Council of Legislators from Gaming States ( ... states with casinos and other forms of state-regulated ... encouraging states to take action to make all ... NCLGS 2009 Winter Meeting, held last weekend in ...
Cached Medicine News:Health News:Aon Benfield Forecasts Potential Impact on the Insurance Industry Resulting From the Alleged Madoff Scandal 2Health News:IVF Treatments Often Work for Women Under 35 2Health News:IVF Treatments Often Work for Women Under 35 3Health News:Hispanics Respond Poorly to Standard Hepatitis C Therapy 2Health News:Surgeon's Checklist Saves Lives 2Health News:Surgeon's Checklist Saves Lives 3Health News:National Council of Legislators From Gaming States Adopts Resolution Supporting 100% Smokefree Gaming Venues 2
Near PT test card/shorthand /PH stock market 5 1/2 " X 8"...
Near and far chart set provides letter and number matrix for testing and accommodative vision training. Set includes 1-8 1/2 X 11 chart on white card with black print and 2-3X5 laminated white card w...
... NP Card is specially designed to be a ... older Rosenbaum card (as noted by Horton and ... The "J" notations are not used because of ... Using the Wormington NP Card, the examiner can ...
Spanish reading test....
Medicine Products: